ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

All Content

Ovarian cancer progression may be driven by the activation of an endoplasmic reticulum stress response factor that disrupts the function of dendritic cells and, subsequently, antitumor fighting T cells.

Two phase III trials have confirmed the benefit of regorafenib, an oral multikinase inhibitor, in patients with previously treated metastatic colorectal cancer.

A subgroup analysis of the phase III RECOURSE trial has shown that TAS-102 is effective at improving survival in patients with both KRAS wild-type or mutant metastatic colorectal cancer.

Treatment with FOLFOX plus cetuximab resulted in improved PFS vs FOLFOX alone in patients with metastatic colorectal cancer with “all-RAS” wild-type tumors.

Use of post-operative radiotherapy was associated with better overall survival in patients with incompletely resected stage II/III non-small-cell lung cancer.

Use of a VD regimen alone to treat patients with transplant-ineligible multiple myeloma was not inferior to VTD or VMP regimens, according to the UPFRONT trial.

Large proportions of lung and colorectal cancer patients believe that surgery will cure their cancer, according to results of a new population-based study.

A new study has found that in patients diagnosed with metastatic colorectal cancer, a low BMI could be a poor prognostic factor.

Nivolumab Trumps Ipilimumab for Treatment-Naive Metastatic Melanoma

This slide show highlights some of the top studies and news on cancer to come out of the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.

Adding the oral NK1 antagonist aprepitant to an oxaliplatin-based chemotherapy regimen effectively reduced nausea and vomiting in colorectal cancer patients.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.